Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy

Al18F-HER2-BCH PET/CT to Predict Response in Breast Patients Treated With ADC Therapy

To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with ADC therapy

Inclusion Criteria:

1. Aged ≥18 years old; ECOG 0 or 1;
2. Patients with HER2 positive or low tumors;
3. Receives neoadjuvant therapy
4. Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions;
5. Life expectancy > 3 months -

Exclusion Criteria:

1. Significant hepatic or renal dysfunction;
2. Is pregnant or ready to pregnant;
3. Cannot keep their states for half an hour;
4. Refused to join the clinical research;
5. Suffering from claustrophobia or other mental disorders;
6. Any other situation that researchers considered it unsuitable to participate in the trial.